Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 10/20 | 0.54 |
| ▸ | CA9 | Q16790 | 5/20 | 0.54 |
| ▸ | CA12 | O43570 | 5/20 | 0.54 |
| ▸ | HCAR3 | P49019 | 5/20 | 0.53 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | RPA1 | P27694 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1092 | 0.85 | HCAR3 (0.54) | ALPLCA9CA12HCAR3HCAR2 | |
| SCHEMBL16763221 | 0.83 | HCAR3 (0.50) | ALPLCA9CA12HCAR3HCAR2 | |
| Hydrochloric Acid SCHEMBL31467460 | 0.83 | HCAR3 (0.53) | ALPLCA9CA12HCAR3HCAR2 | |
| SCHEMBL27865500 | 0.82 | ALPL (0.38) | ALPLCA9CA12HCAR3HCAR2 | |
| SCHEMBL3576102 | 0.82 | PLA2G10 (0.44) | ALPLCA9CA12HCAR3HCAR2 | |
| SCHEMBL1527555 | 0.82 | HCAR2 (0.53) | ALPLCA9CA12HCAR3HCAR2 | |
| SCHEMBL26054148 | 0.82 | TP53 (0.47) | ALPLCA9CA12HCAR3HCAR2 | |
| Hydrochloric Acid SCHEMBL27449787 | 0.80 | HCAR2 (0.51) | ALPLCA9CA12HCAR3HCAR2 | |
| SCHEMBL4790447 | 0.80 | HCAR2 (0.54) | ALPLCA9CA12HCAR3HCAR2 | |
| SCHEMBL6110959 | 0.80 | ALPL (0.46) | ALPLCA9CA12HCAR3HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025082467-A1 | IMMUNOMODULATORS | 成都先导药物开发股份有限公司 | 2025-04-24 | — | — | WO | disclosed |
| CN-110272389-B | Method for synthesizing 4-polyfluoroalkyl-3, 5-dicarbonyl pyrazole compound | 福州大学 | 2022-11-11 | — | — | CN | disclosed |
| CN-112239428-B | Ketone-substituted heterocyclic compounds and their anesthetic action | 成都麻沸散医药科技有限公司 | 2022-06-03 | — | — | CN | disclosed |
| CN-112174890-B | Ketone-substituted heterocyclic compounds and their anesthetic action | 成都麻沸散医药科技有限公司 | 2022-05-27 | — | — | CN | disclosed |
| CN-114341126-A | Process for preparing carboxylic acid derivatives of 3-halo-4, 5-dihydro-1H-pyrazole | FMC公司 | 2022-04-12 | — | — | CN | disclosed |
| CN-112239428-A | Ketone-substituted heterocyclic compounds and their anesthetic action | 成都麻沸散医药科技有限公司 | 2021-01-19 | — | — | CN | disclosed |
| CN-112174890-A | Ketone-substituted heterocyclic compounds and their anesthetic action | 成都麻沸散医药科技有限公司 | 2021-01-05 | — | — | CN | disclosed |
| US-20190321333-A1 | CARBOXAMIDE DERIVATIVE AND ITS DIASTEREOMERS IN STABLE CRYSTALLINE FORM | ORION CORP (FI) | 2019-10-24 | — | — | US | disclosed |
| US-10376494-B2 | Carboxamide derivative and its diastereomers in stable crystalline form | ORION CORPORATION (FI) | 2019-08-13 | — | — | US | disclosed |
| CN-105037346-B | Pyrazoles bisamide class compound and its synthetic method and application of the one kind containing 1,2,3 thiadiazoles | 中国农业大学 | 2017-12-22 | — | — | CN | disclosed |
| EP-1092720-A2 | Process for the preparation of pyrazolo [4,3-d] pyrimidin-7-ones-3-pyridylsulphonyl compounds and intermediates thereof | Pfizer Limited (GB) | 2001-04-18 | — | — | EP | disclosed |
| US-6207829-B1 | CYCLIZATION OF A CORRESPONDING PYRAZOLE COMPOUND | PFIZER INC. | 2001-03-27 | — | — | US | disclosed |
| EP-1073658-A1 | PYRAZOLOPYRIMIDINONE CGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | PFIZER INC. (US) | 2001-02-07 | — | — | EP | disclosed |
| CN-1255497-A | Process for preparing pyrazolo [4, 3-d ] pyrimidin-7-ones and intermediates thereof | PFIZER RES & DEV (IE) | 2000-06-07 | — | — | CN | disclosed |
| CN-1253561-A | Pyrazolopyrimidinones inhibiting type 5 cyclic guanosine 3',5' -monophosphate phosphodiesterase (cGMP PDE5) for the treatment of sexual dysfunction | PFIZER LTD (US) | 2000-05-17 | — | — | CN | disclosed |
| EP-0995750-A1 | Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction | PFIZER INC. (US) | 2000-04-26 | — | — | EP | disclosed |
| EP-0994115-A2 | Process for preparation of pyrazolo-(4,3-d)pyrimidin-7-ones and intermediates thereof | Pfizer Limited (GB) | 2000-04-19 | — | — | EP | disclosed |
| EP-0977756-A1 | PYRAZOLOPYRIMIDINONES WHICH INHIBIT TYPE 5 CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE (cGMP PDE5) FOR THE TREATMENT OF SEXUAL DYSFUNCTION | Pfizer Limited (GB) | 2000-02-09 | — | — | EP | disclosed |
| WO-1999054333-A1 | PYRAZOLOPYRIMIDINONE CGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | PFIZER INC. (US) | 1999-10-28 | — | — | WO | disclosed |
| WO-1998049166-A1 | PYRAZOLOPYRIMIDINONES WHICH INHIBIT TYPE 5 CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE (cGMP PDE5) FOR THE TREATMENT OF SEXUAL DYSFUNCTION | PFIZER LIMITED (GB) | 1998-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10376494-B2 | Carboxamide derivative and its diastereomers in stable crystalline form | AR, NR5A1, SHBG | ALPL 3096/4885CA9 1915/4885CA12 1560/4885 |
| US-20190321333-A1 | CARBOXAMIDE DERIVATIVE AND ITS DIASTEREOMERS IN STABLE CRYSTALLINE FORM | AR, NR5A1, SHBG | ALPL 3096/4885CA9 1915/4885CA12 1560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.